Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
-2.92%
-2.08%
+9.79%
-19.01%
-3.34%
BDSX
Biodesix
$0.30
Chart
$0.49 (-38.78%)
$0.86 (-65.12%)
$0.9 (-66.67%)
$1.6 (-81.25%)
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-2.92%
-2.08%
+9.79%
-19.01%
-3.34%
BDSX
Biodesix
Current Price
$0.30
Login to view Biodesix (BDSX) recommendation from the last 90 days from financial news and social media.
Chart
$0.49 (-38.78%)
$0.86 (-65.12%)
$0.9 (-66.67%)
$1.6 (-81.25%)
BDSX Latest Headlines
Whats Behind The Big Stock Moves? BDSX APLM RNAZ... . (RTTNews) - Shares of Biodesix Inc. (BDSX) are up over 80% at $0.48. This diagnostic solutions company offers blood-based lung tests to assess the risk of lung cancer is scheduled to participate in the 22nd Annual Craig-Hallum Institutional Investor Conference on May 28 2025.
Wed May 21, 2025
Biodesix to Participate in Upcoming Investor Conferences. LOUISVILLE Colo. May 21 2025 (GLOBE NEWSWIRE) -- Biodesix Inc. (NASDAQ:) a leading diagnostic solutions company today announced that members of the Biodesix management team will participate in two upcoming investor conferences:1x1 MeetingsDate: Wednesday May 28 2025 Location: Minneapolis MNPresentation and 1x1 Meetings
Wed May 21, 2025
Why Toll Brothers Shares Are Trading Higher By Over 6%. Here Are 20 Stocks Moving Premarket. Shares of ) rose sharply in today'.s pre-market after the company posted stronger-than-expected earnings and sales results for the second quarter.The company reported quarterly earnings of $3.50 per share which beat the analyst consensus estimate of $2.92 by 19.86%. Quarterly revenue came in at $2.71 billion which beat the Street estimate of $2.48 billion.Toll Brothers shares jumped 6.1% to $110.86 i
Wed May 21, 2025
Why Toll Brothers Shares Are Trading Higher By Over 6%. Here Are 20 Stocks Moving Premarket. Shares of ) rose sharply in today'.s pre-market after the company posted stronger-than-expected earnings and sales results for the second quarter.The company reported quarterly earnings of $3.50 per share which beat the analyst consensus estimate of $2.92 by 19.86%. Quarterly revenue came in at $2.71 billion which beat the Street estimate of $2.48 billion.Toll Brothers shares jumped 6.1% to $110.86 i
Wed May 21, 2025
Why Toll Brothers Shares Are Trading Higher By Over 6%. Here Are 20 Stocks Moving Premarket. Shares of ) rose sharply in today'.s pre-market after the company posted stronger-than-expected earnings and sales results for the second quarter.The company reported quarterly earnings of $3.50 per share which beat the analyst consensus estimate of $2.92 by 19.86%. Quarterly revenue came in at $2.71 billion which beat the Street estimate of $2.48 billion.Toll Brothers shares jumped 6.1% to $110.86 i
Wed May 21, 2025
Biodesix GAAP EPS of -$0.08 misses by $0.02 revenue of $18M misses by $3.23M.
Wed May 14, 2025
Biodesix Analysts Lower Their Forecasts After Downbeat Q1 Results. ) reported weaker-than-expected results for the first quarter on Tuesday.The company posted quarterly losses of 8 cents per share which missed the analyst consensus estimate of losses of 7 cents per share. The company reported quarterly sales of $17.96 million which missed the analyst consensus estimate of $19.47 million.“.Our quarter was highlighted by continued progress toward our three key goals for 2025 – growing top lin
Wed May 14, 2025
Biodesix Analysts Lower Their Forecasts After Downbeat Q1 Results. ) reported weaker-than-expected results for the first quarter on Tuesday.The company posted quarterly losses of 8 cents per share which missed the analyst consensus estimate of losses of 7 cents per share. The company reported quarterly sales of $17.96 million which missed the analyst consensus estimate of $19.47 million.“.Our quarter was highlighted by continued progress toward our three key goals for 2025 – growing top lin
Wed May 14, 2025
Biodesix revises 2025 revenue guidance to $80M–$85M amid sales force reconfiguration and primary care expansion.
Tue May 13, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
BDSX Stock trends
BDSX Stock performance
BDSX Stock analysis
BDSX investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Hover over the category for more information
